Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS
· Delayed Price · Currency is USD
0.0180
-0.0062 (-25.62%)
Apr 4, 2025, 3:47 PM EDT
Syros Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Revenue | 0.39 | 9.94 | 14.88 | 23.49 | 15.09 | 1.98 | Upgrade
|
| Revenue Growth (YoY) | -95.61% | -33.23% | -36.65% | 55.62% | 661.50% | -3.32% | Upgrade
|
| Cost of Revenue | 88.64 | 108.15 | 111.94 | - | - | - | Upgrade
|
| Gross Profit | -88.25 | -98.22 | -97.06 | 23.49 | 15.09 | 1.98 | Upgrade
|
| Selling, General & Admin | 23.27 | 28.28 | 29.3 | 23.04 | 21.33 | 21.48 | Upgrade
|
| Research & Development | - | - | - | 99.87 | 76.07 | 58.25 | Upgrade
|
| Operating Expenses | 23.27 | 28.28 | 29.3 | 122.91 | 97.39 | 79.72 | Upgrade
|
| Operating Income | -111.52 | -126.5 | -126.36 | -99.42 | -82.3 | -77.74 | Upgrade
|
| Interest Expense | -5.33 | -5.13 | -4.13 | -3.91 | -1.79 | -0.07 | Upgrade
|
| Interest & Investment Income | 4.71 | 6.82 | 2.13 | 0.09 | 0.43 | 2.38 | Upgrade
|
| Other Non Operating Income (Expenses) | 14.47 | -37.28 | 33.71 | 16.68 | -0.38 | - | Upgrade
|
| EBT Excluding Unusual Items | -97.68 | -162.09 | -94.65 | -86.56 | -84.04 | -75.44 | Upgrade
|
| Merger & Restructuring Charges | -0.14 | -2.49 | - | - | - | - | Upgrade
|
| Pretax Income | -97.82 | -164.57 | -94.65 | -86.56 | -84.04 | -75.44 | Upgrade
|
| Net Income | -97.82 | -164.57 | -94.65 | -86.56 | -84.04 | -75.44 | Upgrade
|
| Net Income to Common | -97.82 | -164.57 | -94.65 | -86.56 | -84.04 | -75.44 | Upgrade
|
| Shares Outstanding (Basic) | 37 | 28 | 13 | 6 | 5 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 37 | 28 | 13 | 6 | 5 | 4 | Upgrade
|
| Shares Change (YoY) | 31.77% | 124.24% | 102.00% | 35.79% | 14.49% | 23.17% | Upgrade
|
| EPS (Basic) | -2.66 | -5.81 | -7.49 | -13.84 | -18.25 | -18.76 | Upgrade
|
| EPS (Diluted) | -2.66 | -5.81 | -7.49 | -13.84 | -18.25 | -18.76 | Upgrade
|
| Free Cash Flow | -100.05 | -109.98 | -124.31 | -100.79 | -60.7 | -72.89 | Upgrade
|
| Free Cash Flow Per Share | -2.72 | -3.88 | -9.84 | -16.12 | -13.18 | -18.12 | Upgrade
|
| Gross Margin | - | - | - | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -28891.71% | -1273.14% | -849.21% | -423.28% | -545.27% | -3922.35% | Upgrade
|
| Profit Margin | -25340.67% | -1656.34% | -636.12% | -368.52% | -556.80% | -3806.15% | Upgrade
|
| Free Cash Flow Margin | -25920.72% | -1106.87% | -835.39% | -429.09% | -402.17% | -3677.65% | Upgrade
|
| EBITDA | -110.18 | -124.25 | -123.66 | -96.4 | -79.26 | -75.02 | Upgrade
|
| D&A For EBITDA | 1.34 | 2.25 | 2.71 | 3.02 | 3.04 | 2.72 | Upgrade
|
| EBIT | -111.52 | -126.5 | -126.36 | -99.42 | -82.3 | -77.74 | Upgrade
|
Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.